Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 11/20 | 1.00 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.81 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.78 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.78 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | IKBKB | O14920 | 1/20 | 0.66 |
| ▸ | CHUK | O15111 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MYLK | Q15746 | 1/20 | 0.66 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454776 | 1.00 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438716 | 0.93 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL30692659 | 0.93 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438051 | 0.91 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL30692660 | 0.91 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL23685650 | 0.90 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL23675471 | 0.90 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL13812666 | 0.90 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL17845883 | 0.90 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438815 | 0.90 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | claimed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| CN-105911162-B | The assay method of bromo and Chlorosalicylic anilide in a kind of cosmetics | 中国检验检疫科学研究院 | 2018-01-26 | — | — | CN | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| CN-105911162-A | Method for determining brominated and chlorinated salicylanilide in cosmetics | 中国检验检疫科学研究院 | 2016-08-31 | — | — | CN | claimed |
| EP-3653303-B1 | PIPETTE TIP RACK | BIOTIX INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12201987-B2 | Pipette tip rack | BIOTIX, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4376673-B1 | FILAMENTS FOR ORAL CARE IMPLEMENTS | UNILEVER IP HOLDINGS B V (NL) | 2025-01-01 | — | — | EP | disclosed |
| CN-118042960-A | Filaments for oral care implements | 联合利华知识产权控股有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2003049776-A1 | ANTIMICROBIAL CONTACT LENS CASE | NOVARTIS AG (CH) | 2003-06-19 | — | — | WO | disclosed |
| US-20030108761-A1 | Anti-bacterial paper products | EDDLEMON TAMMY (US) | 2003-06-12 | — | — | US | disclosed |
| US-6138315-A | Antimicrobial active compounds | CHESEBROUGH-POND'S USA CO., DIVISON OF CONOPCO, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5919152-A | Antibacterial swabs | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| US-5846215-A | Antibacterial swabs | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-4022880-A | ZINC IONS, 3,4,5-TRIBROMO-SALICYLANILIDE, QUATERNARY AMMONIUM COMPOUNDS | LEVER BROTHERS COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4010252-A | POLYQUATERNARY AMMONIUM COMPOUND, DEODORANTS | COLGATE-PALMOLIVE COMPANY (US) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | ACE2, ACE, TMPRSS2 | P2RX1 2669/4885TMPRSS4 14/4885P2RX4 3287/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | P2RX1 3423/4885TMPRSS4 2074/4885P2RX4 3784/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | P2RX1 910/4885TMPRSS4 2067/4885P2RX4 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.